Daily Oncology/Cancer News | Treatment, Research Articles

Daily Oncology News

Opdivo Plus Yervoy With Limited Chemotherapy Approved for First-Line Metastatic or Recurrent NSCLC

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

Skin Cancer Clinical Trials

Next post in Daily Oncology News